Bone Marrow Therapy: The Good, the Bad & the Ugly
Bone Marrow treatments in Clovis, CA have been developed to treat a whole host of illnesses. Stem therapy can treat missing teeth, baldness, and blindness, as well as degenerative illnesses like type 1 diabetes, Parkinson’s, heart failure, and even cancer. Bone Marrow treatments are usually a less invasive, more viable, and more sustainable therapeutic approach than similar methods like organ transplantation. Let us throw some light on good, bad and ugly Bone Marrow therapies.
Good Bone Marrow Therapies
There are usually 3 types of Good stem therapies which can be derived from bone marrow, peripheral blood, or umbilical cord blood. Bone marrow transplantation is the most famous form of Bone Marrow therapy and the only Bone Marrow therapy in common use. It is used to treat leukemia and other disorders of the bone marrow and the blood.
Peripheral blood Bone Marrows and Umbilical Cord Blood Bone Marrows can also be used instead of bone marrow samples to re-generate the bone marrow in the procedure of bone marrow transplantation.
Ugly Bone Marrow Therapies
The ugly thing about unethical people selling unregulated Bone Marrow products is that innocent people get hurt. Many negative effects go unreported. Ugly Bone Marrow Therapies include painful and in-effective procedures to remove tissues from a person’s body like Bone marrow aspirate. While bone marrow aspirates are safe, still all medical procedures involve some type of risk. Possible complications are, excessive bleeding, infection, allergic reaction to anesthesia and long-lasting discomfort.
Bad Bone Marrow Therapies:
According to research, SVF (Stromal Vascular Fraction) derived from either placenta or fat did not meet the international standard definition of a Bone Marrow therapy. This is the reason SVF cannot be called a Bone Marrow product. SVF is regarded as harmful to Bone Marrows expanded from fat or placenta in terms of potency. Anyone who buys this should be aware of this product as harmful and ineffective.
The bottom line is that cell processing standards should be refined and followed, cells are tested in proper clinical trial settings with consistent follow-up and long-term monitoring.